Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5520
Abstract: 5520Background: We previously demonstrated that bevacizumab may differentially improve ovarian cancer progression-free survival (PFS) depending on TCGA molecular subtypes. Despite recent progress i... read more here.
Keywords: survival improvement; ovarian cancer; cancer; overall survival ... See more keywords